$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024035170 Filed on August 06, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$117.1M	$109.3M
YoY Change	34.98%	32.54%
Cost Of Revenue	$3.211M	$1.699M
YoY Change	192.17%	78.84%
Gross Profit	$113.9M	$107.6M
YoY Change	32.96%	32.0%
Gross Profit Margin	97.26%	98.45%
Selling, General & Admin	$65.08M	$61.21M
YoY Change	28.5%	20.03%
% of Gross Profit	57.15%	56.87%
Research & Development	$41.08M	$37.62M
YoY Change	-12.37%	-26.58%
% of Gross Profit	36.08%	34.95%
Depreciation & Amortization	$311.0K	$320.0K
YoY Change	-25.95%	-21.38%
% of Gross Profit	0.27%	0.3%
Operating Expenses	$106.2M	$98.84M
YoY Change	8.86%	-3.33%
Operating Profit	$7.692M	$8.761M
YoY Change	-164.52%	-142.32%
Interest Expense	-$21.14M	$24.73M
YoY Change	-177.3%	-199.47%
% of Operating Profit	-274.82%	282.31%
Other Income/Expense, Net
YoY Change
Pretax Income	-$13.45M	-$12.50M
YoY Change	-62.46%	-83.24%
Income Tax	$586.0K	$172.0K
% Of Pretax Income
Net Earnings	-$14.03M	-$12.67M
YoY Change	-61.18%	-83.17%
Net Earnings / Revenue	-11.99%	-11.59%
Basic Earnings Per Share	-$0.07	-$0.06
Diluted Earnings Per Share	-$0.07	-$0.06
COMMON SHARES
Basic Shares Outstanding	206.9M shares	206.4M shares
Diluted Shares Outstanding	206.9M shares	206.4M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$330.0M	$272.0M
YoY Change	-17.0%	-33.76%
Cash & Equivalents	$96.84M	$78.41M
Short-Term Investments	$233.2M	$193.6M
Other Short-Term Assets	$17.09M	$18.22M
YoY Change	-20.86%	16.16%
Inventory	$7.562M	$4.450M
Prepaid Expenses
Receivables	$72.46M	$68.76M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$427.1M	$363.5M
YoY Change	-14.99%	-28.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.421M	$7.663M
YoY Change	-17.54%	-9.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$19.43M	$64.32M
YoY Change		1766.97%
Other Assets	$15.65M	$12.46M
YoY Change	36.57%	79.34%
Total Long-Term Assets	$64.13M	$109.0M
YoY Change	213.47%	478.69%
TOTAL ASSETS
Total Short-Term Assets	$427.1M	$363.5M
Total Long-Term Assets	$64.13M	$109.0M
Total Assets	$491.3M	$472.4M
YoY Change	-6.06%	-10.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.48M	$7.786M
YoY Change	27.59%	-43.94%
Accrued Expenses	$104.2M	$89.60M
YoY Change	34.64%	18.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$34.84M	$30.66M
YoY Change
Total Short-Term Liabilities	$153.6M	$129.1M
YoY Change	69.2%	38.04%
LONG-TERM LIABILITIES
Long-Term Debt	$314.3M	$313.8M
YoY Change	5.48%	7.04%
Other Long-Term Liabilities	$8.065M	$8.362M
YoY Change	-19.35%	44.1%
Total Long-Term Liabilities	$314.3M	$313.8M
YoY Change	5.48%	7.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$153.6M	$129.1M
Total Long-Term Liabilities	$314.3M	$313.8M
Total Liabilities	$959.8M	$442.9M
YoY Change	146.89%	14.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.743B	-$1.729B
YoY Change	7.65%	9.22%
Common Stock	$2.071M	$2.066M
YoY Change	9.11%	9.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$468.6M	-$475.6M
YoY Change
Total Liabilities & Shareholders Equity	$491.3M	$472.4M
YoY Change	-6.06%	-10.84%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$14.03M	-$12.67M
YoY Change	-61.18%	-83.17%
Depreciation, Depletion And Amortization	$311.0K	$320.0K
YoY Change	-25.95%	-21.38%
Cash From Operating Activities	$8.245M	-$1.368M
YoY Change	-141.45%	-92.73%
INVESTING ACTIVITIES
Capital Expenditures	$59.00K	$155.0K
YoY Change	-93.98%	-66.81%
Acquisitions
YoY Change
Other Investing Activities	$8.548M	-$2.294M
YoY Change	-64.55%	-87.65%
Cash From Investing Activities	$8.489M	-$2.449M
YoY Change	-63.27%	-87.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.274M	-1.966M
YoY Change	3.58%	-106.7%
NET CHANGE
Cash From Operating Activities	8.245M	-1.368M
Cash From Investing Activities	8.489M	-2.449M
Cash From Financing Activities	1.274M	-1.966M
Net Change In Cash	18.01M	-5.783M
YoY Change	304.67%	-31.91%
FREE CASH FLOW
Cash From Operating Activities	$8.245M	-$1.368M
Capital Expenditures	$59.00K	$155.0K
Free Cash Flow	$8.186M	-$1.523M
YoY Change	-139.22%	-92.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	206425000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-35379000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	552000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	109332000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	82491000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	8761000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20703000	usd
CY2023Q2	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	301000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AvailableForSaleSecuritiesDebtSecuritiesCurrent
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AvailableForSaleSecuritiesDebtSecuritiesCurrent
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	206629000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	206629000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	205771000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	205771000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2066000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2058000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1250983000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1222236000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	557000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1337000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1729212000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1681159000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-475606000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-455528000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	472419000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	516960000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	109332000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	82491000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1699000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	894000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37623000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51247000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61214000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	50997000	usd
CY2024Q2	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	35000	usd
CY2023Q2	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	56000	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	100571000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	103194000	usd
CY2024Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	3554000	usd
CY2023Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	3750000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	24733000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	28915000	usd
	us-gaap	Interest Expense InterestExpense	49239000	usd
	us-gaap	Interest Expense InterestExpense	56311000	usd
CY2024Q2	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-84000	usd
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-29019000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12502000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74586000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	172000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	740000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-12674000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-75326000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-140000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	59000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-74000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	46000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12888000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75221000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	206425000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188815000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188815000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-48053000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-128659000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	626000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	812000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	238000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	26825000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	26848000	usd
	bcrx	Non Cash Interest Expense On Royalty Financing Liabilities And Secured Term Loan And Amortization Of Debt Issuance Costs NonCashInterestExpenseOnRoyaltyFinancingLiabilitiesAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts	39041000	usd
	bcrx	Non Cash Interest Expense On Royalty Financing Liabilities And Secured Term Loan And Amortization Of Debt Issuance Costs NonCashInterestExpenseOnRoyaltyFinancingLiabilitiesAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts	43935000	usd
	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-6674000	usd
	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-4217000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-29019000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	12085000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	6968000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	481000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1029000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2851000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1484000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-57103000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27414000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	535000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55052000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66326000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	390000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	627000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	200303000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	233530000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	227000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	108013000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26307000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-126144000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1945000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6825000	usd
	bcrx	Proceeds From Issuance Of Common Stock Issued For Services ProceedsFromIssuanceOfCommonStockIssuedForServices	23000	usd
	bcrx	Proceeds From Issuance Of Common Stock Issued For Services ProceedsFromIssuanceOfCommonStockIssuedForServices	206000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4190000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	300000000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	240452000	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	21261000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	10885000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	792000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3014000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34433000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-483000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-413000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32242000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-158450000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112447000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	306239000	usd
	us-gaap	Interest Paid Net InterestPaidNet	10041000	usd
	us-gaap	Interest Paid Net InterestPaidNet	12300000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	865000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1126000	usd
	bcrx	Withholding Taxes Accrued WithholdingTaxesAccrued	189000	usd
	bcrx	Withholding Taxes Accrued WithholdingTaxesAccrued	2188000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-455528000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-566000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	38000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1129000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13652000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-476167000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-12674000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-214000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	264000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	12000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13173000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-475606000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-294597000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-53333000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	559000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3502000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1575000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14007000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-328287000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-75326000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	105000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1748000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	206000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12841000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-388713000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company’s condensed consolidated financial statements have been made relative to the calculation of net product sales, the ORLADEYO and Factor D inhibitors royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company’s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	109332000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	82491000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	202093000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	151269000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1795000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1804000	usd
	bcrx	Long Term Investment Maturity Minimum LongTermInvestmentMaturityMinimum	P12M
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44999000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	55208000	shares
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	usd
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	202093000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	151269000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	257934000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	19	security
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	238945000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	257288000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	955000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	315000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	257934000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	278131000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	135000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	150000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	72000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	193617000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	278344000	usd
CY2024Q2	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	64317000	usd
CY2023Q4	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	257934000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2024Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	2119000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	2296000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	7597000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6449000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	14480000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	17591000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8498000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6242000	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	30575000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	30282000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1600000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1599000	usd
CY2024Q2	bcrx	Inventory Including Noncurrent Portion InventoryIncludingNoncurrentPortion	28975000	usd
CY2023Q4	bcrx	Inventory Including Noncurrent Portion InventoryIncludingNoncurrentPortion	28683000	usd
CY2023Q4	bcrx	Royalty Financing Liabilities RoyaltyFinancingLiabilities	531599000	usd
CY2024Q1	bcrx	Non Cash Interest Expense On Royalty Financing Liabilities NonCashInterestExpenseOnRoyaltyFinancingLiabilities	14187000	usd
CY2024Q1	bcrx	Royalty Revenues Paid And Payable RoyaltyRevenuesPaidAndPayable	-15212000	usd
CY2024Q1	bcrx	Royalty Financing Liabilities RoyaltyFinancingLiabilities	530574000	usd
CY2024Q2	bcrx	Non Cash Interest Expense On Royalty Financing Liabilities NonCashInterestExpenseOnRoyaltyFinancingLiabilities	14263000	usd
CY2024Q2	bcrx	Royalty Revenues Paid And Payable RoyaltyRevenuesPaidAndPayable	-21204000	usd
CY2024Q2	bcrx	Royalty Financing Liabilities RoyaltyFinancingLiabilities	523633000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	582000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	460000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1172000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	893000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	416000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	267000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	823000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	523000	usd
CY2024Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	73000	usd
CY2023Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	37000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	150000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	75000	usd
CY2024Q2	bcrx	Financing Lease Expense FinancingLeaseExpense	489000	usd
CY2023Q2	bcrx	Financing Lease Expense FinancingLeaseExpense	304000	usd
	bcrx	Financing Lease Expense FinancingLeaseExpense	973000	usd
	bcrx	Financing Lease Expense FinancingLeaseExpense	598000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y8M12D
CY2024Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1090
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1088
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0770
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0746
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8535000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8682000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1026000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8362000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8390000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	9388000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9448000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3653000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4322000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1681000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1590000	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2117000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2845000	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	3798000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4435000	usd
CY2024Q2	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	5444000	usd
CY2023Q4	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	4794000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	3116000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	2293000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1028000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	953000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1849000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1782000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1660000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	948000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1584000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	474000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1416000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	38000	usd
CY2024Q2	bcrx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	7997000	usd
CY2024Q2	bcrx	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15534000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	4195000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6146000	usd
CY2024Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	397000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	9388000	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	3798000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	150000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	576000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1084000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	874000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	792000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	156000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	350000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	155000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	610000	usd
	bcrx	Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities	365000	usd
	bcrx	Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities	0	usd
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	64158000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	58020000	shares
CY2024Q2	bcrx	Share Based Payment Arrangement Number Of Plans ShareBasedPaymentArrangementNumberOfPlans	3	plan
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13173000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12841000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26825000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26848000	usd
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	251000	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	176000	shares
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	3380000	usd
CY2024Q1	us-gaap	Restructuring Costs RestructuringCosts	1264000	usd
CY2024Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	3168000	usd
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	1476000	usd
CY2024Q2	us-gaap	Restructuring Costs RestructuringCosts	0	usd
CY2024Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	1179000	usd
CY2024Q2	us-gaap	Restructuring Reserve RestructuringReserve	297000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-035170-index-headers.html	Edgar Link	pending
0001628280-24-035170-index.html	Edgar Link	pending
0001628280-24-035170.txt	Edgar Link	pending
0001628280-24-035170-xbrl.zip	Edgar Link	pending
bcrx-20240630.htm	Edgar Link	pending
bcrx-20240630.xsd	Edgar Link	pending
bcrx-20240630xexx311.htm	Edgar Link	pending
bcrx-20240630xexx312.htm	Edgar Link	pending
bcrx-20240630xexx321.htm	Edgar Link	pending
bcrx-20240630xexx322.htm	Edgar Link	pending
exhibit102-biocrystxfirsta.htm	Edgar Link	pending
exhibit103-biocrystpharmac.htm	Edgar Link	pending
exhibit104-biocrystsipperf.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
bcrx-20240630_cal.xml	Edgar Link	unprocessable
bcrx-20240630_def.xml	Edgar Link	unprocessable
bcrx-20240630_lab.xml	Edgar Link	unprocessable
bcrx-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bcrx-20240630_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2024 Q3 Form 10-Q Financial Statement

#000162828024035170 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2024 Q3 Form 10-Q Financial Statement

#000162828024035170 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx